Page last updated: 2024-09-03

imatinib mesylate and Allergic Reaction

imatinib mesylate has been researched along with Allergic Reaction in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (66.67)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Krishnamoorthy, N; Oriss, TB; Ray, A; Ray, P1
Di, YW; Liu, YH; Zhuang, HG1
Gross, WL; Hellmich, B; Holl-Ulrich, K1

Reviews

2 review(s) available for imatinib mesylate and Allergic Reaction

ArticleYear
Dendritic cell c-kit signaling and adaptive immunity: implications for the upper airways.
    Current opinion in allergy and clinical immunology, 2014, Volume: 14, Issue:1

    Topics: Adaptive Immunity; Animals; Benzamides; Cytokines; Dendritic Cells; Humans; Hypersensitivity; Imatinib Mesylate; Killer Cells, Natural; Lymphocyte Activation; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Respiratory System; Signal Transduction; Stem Cell Factor; Th1-Th2 Balance; Th17 Cells; Th2 Cells

2014
[Hypereosinophilic syndrome--recent developments in diagnosis and treatment].
    Deutsche medizinische Wochenschrift (1946), 2007, Volume: 132, Issue:37

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Glucocorticoids; Humans; Hypereosinophilic Syndrome; Hypersensitivity; Imatinib Mesylate; Immunosuppressive Agents; Interferon-alpha; Lung Diseases; Neoplasms; Parasitic Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Tumor Necrosis Factor-alpha; Vasculitis

2007

Other Studies

1 other study(ies) available for imatinib mesylate and Allergic Reaction

ArticleYear
[Eosinophils and related diseases].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2009, Volume: 38, Issue:7

    Topics: Antineoplastic Agents; Autoimmune Diseases; Benzamides; Cell Differentiation; Cell Movement; Cell Survival; Eosinophilia; Eosinophils; Helminthiasis; Humans; Hypereosinophilic Syndrome; Hypersensitivity; Imatinib Mesylate; Piperazines; Pyrimidines

2009